as 01-17-2025 4:00pm EST
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
Founded: | 2017 | Country: | United States |
Employees: | 7 | City: | WEXFORD |
Market Cap: | 22.3M | IPO Year: | N/A |
Target Price: | N/A | AVG Volume (30 days): | 1.0M |
Analyst Decision: | N/A | Number of Analysts: | N/A |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -6.33 | EPS Growth: | N/A |
52 Week Low/High: | $2.31 - $13.58 | Next Earning Date: | 11-13-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
COEP Breaking Stock News: Dive into COEP Ticker-Specific Updates for Smart Investing
PR Newswire
12 days ago
Benzinga
22 days ago
MT Newswires
23 days ago
PR Newswire
23 days ago
PR Newswire
24 days ago
PR Newswire
a month ago
PR Newswire
2 months ago
PR Newswire
2 months ago
The information presented on this page, "COEP Coeptis Therapeutics Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.